Biomagnetics Diagnostics Corp. is an advanced medical device and biotechnology company with a revolutionary diagnostics system and test kit testing technology for HIV, Hepatitis, H-Pylori, HPV, Tuberculosis and many other viruses, bacterium’s, toxins and diseases. The company focuses on real-time testing for the actual presence of the virus/ toxin/ disease itself, instead of the antibodies produced by the body’s immune system which may take anywhere from weeks to months to appear.

The company intends to follow the lead of established Western drugmakers and biotechs Merck & Co. (MRK), Wyeth (WYE), Eli Lilly & Co. (LLY), Schering-Plough (SGP), Novartis (NVS), Sanofi-Aventis (SNY), Genentech (DNA), Bristol Meyers Squibb (BMYS) and many others that are ramping up investments in China, India and Singapore. The company is currently working to establish a separate Chinese operating company that it intends to apply for listing on the Shenzhen or Hong Kong stock exchange.

Biomagnetics is also currently

Enzo Biochem Inc. (NYSE:ENZ) announced today that they have favorable results of the Company’s clinical trial for the treatment of non-alcoholic steatohepatitis. The information was presented by Enzo Biochem at the annual meeting of the American Association for the Study of Liver Diseases. Currently, the causes of NASH are not well-defined due to which there is currently no medical therapy available in the market to combat NASH.

Enzo Biochem is one of the leading biopharmaceuticals companies that is into research and development, manufacturing, licensing of innovative healthcare products and technologies based on molecular biology and genetic engineering techniques. Currently, the Company has around forty thousand products that serve under molecular biology, drug discovery, and pathology research markets. Enzo’s scientists and collaborators have presented the data that showed that oral administration of EGS21 is safe and remains biologically active in the patients with insulin resistance and NASH which leads to the

Clenergen Corporation has taken a unique approach to the problem of using biomass as fuel for power production facilities. The company has approached the issue from an agronomy and plantation management perspective rather than solely from an engineering perspective. Clenergen has achieved the ability to deliver a standard, uniform virgin biomass on a commercial scale at regular intervals over a long period of time.

The company has contractually secured access to the feedstock required for cultivation. One feedstock is a species of grass named ‘Beema Bamboo’ which has been developed and test planted for Clenergen by its partner Growmore Biotech Limited from India. The plant is a perennial with a life span of 50 years and the harvestable biomass yield ranges from 20 million tons per acre in the second year to 60 million tons after four years of cultivation.

A second feedstock

The sequencing of the human genome has resulted in the emergence of an enormously important new branch in the biotechnological sciences. The most common terms for this field are bioinformatics or computational biology.

You may have read about the discovery, recently, of a new and radically more effective mosquito repellent. Based on molecules found in black pepper, it was not discovered using traditional laboratory methods. Instead, it came about through computer simulations based on knowledge of mosquito cell biology. This is just the tip of the bioinformatics iceberg.

Until recently, cell biology has been something of a “black box.” We could observe how cells functioned, but had little insight into the actual mechanisms. Now, though, scientists are learning how cells work on the molecular level.

Using mathematical models and new technologies for detecting molecular processes, researchers are extracting raw data from DNA and modeling the ways genes work and interact. To understand this

Companies featured in this edition of the newsletter: CUR, CVM, ENZ, IMUC, MBCI, ONEZ, PHC, SVUL

Markets finished in positive territory yet again during this holiday shortened week despite the lack of any significant developments on either the corporate or economic fronts. All told, the Dow gained 164 points to close at 9605, up 1.7% on the week and 9.4% on the year. The Nasdaq gained 3.1% on the week, closing at 2080, up 32% on the year, while the S&P 500 and Russell 2000 gained 2.6% and 4.0% respectively on the week, up 15.4% and 18.8% on the year.

It was a slow week on the corporate side, but there were some healthy signals from the technology sector, as Texas Instruments raised its Q3 outlook, guiding for EPS of between $0.37 and $0.41, up from previous forecasts of $0.29-$0.39. Fed Ex also guided higher, citing cost management and better

Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant polymers and high performance fibers, invests in genetic research and targeted product development to create innovative near-term solutions to meet the practical problems of our world. The company is currently working in cooperation with university scientists and laboratories to create new polymers with potentially broad applications for consumers and industry in the $92 billion marketplace for high-performance polymers.

Kraig Biocraft Laboratories develops collaborative relationships with leading universities and funds university scientists and laboratories to create technologies with significant commercial applications through the Kraig Research Initiative. As a part of this program, the company has licensed university intellectual property in the fields of genetics and genetic engineering.

The company sponsors and collaborates on research within various universities’ genetic engineering laboratories. In 2007, Kraig Biocraft Laboratories signed an intellectual property and collaborative research

Kraig Biocraft Laboratories, Inc., the Michigan-based company using genetic engineering to allow silkworms to produce spider silk, is making use of some of the most advanced insect-related genetic engineering techniques known. Scientists have already produced the first transgenic silkworms, and other scientists have discovered the sequence of genes used by spiders to produce silk. The brilliance of Kraig’s approach is the bringing together of researchers from both of these fields in a collaborative effort to produce commercially viable quantities of spider silk.

Kraig Biocraft has acquired the exclusive rights in this field to the genetic sequences patented by the University of Wyoming, and the genetic engineering technology developed by the University of Notre Dame. The company is now working in conjunction with the leading genetic scientists at these universities to produce a transgenic variety of silkworm capable of producing the elusive spider silk.

Kraig Biocraft Laboratories, Inc., the Michigan-based research group best known for its innovative research in genetic engineering for the production of spider silk, is representative of what some are saying will be the 21st century’s most important scientific and industrial movement, biotechnology. Reflecting this is the fact that biotechnology, loosely defined as the application of advanced microbiological sciences for industrial or health objectives, is still the darling of venture capitalists.

According to a Reuters article by David Lawsky, “Biotechnology leapt ahead as the biggest recipient of U.S. venture capital money in the second quarter”, indicating that “the venture capital industry put $3.67 billion into 612 separate companies or deals during the second quarter, of which $1.5 billion involved first time funding”, though the article went on to say that funding was still well below levels earlier in the decade.

The article quoted Tracy

Resource legend tips his hat to three soon-to-bubble sectors… The housing market has “bottomed out” says PNC… our gentle retort… Alan Knuckman with an economic indicator far superior to unemployment: chicken sales… Our panel of “whiskey shooters” on the worst-case scnerio… how to get out of Dodge if the dollar collapses… Britian now REALLY in crisis… recession, taxes cause wave of pub shutdowns…

Let’s make some trades this morning. We asked Rick Rule, a living legend here in Vancouver, what’s the next bubble market? “The Canadian market does not care about small oil and gas companies,” he told us yesterday. “Which means that small Canadian O&G companies are selling for 50-60% of net asset value. They are very, very, very cheap. They are unloved, with no finance options and no trading liquidity… and I love that. This value is free. There will be much money made in small-cap

Kraig Biocraft Laboratories, Inc., the biotech company known for its pioneering work in genetic engineering for the production of spider silk and other polymers, is constantly breaking new ground in the field of genetics. As such, it is not surprising that they have assembled a remarkable team of scientific advisors to play a major role in everything they do.

• Malcolm J. Fraser, Jr., Ph.D, specializes in molecular genetics, and currently heads the Fraser Laboratory at the University of Notre Dame. During his post-doctoral work at Texas A&M, Dr. Fraser was part of the team which developed the genetic expression system for producing organic molecules, including pharmaceuticals, on an industrial scale. He is the co-inventor of the “piggyBac” gene splicing technology, and the named inventor for various patents involving its improvement.

He was recently selected as a fellow of the American Association for the Advancement